ZLDPF
Zealand Pharma A/S$33.88 −0.62 (−1.80%)
Oct 23 4:00 PM ET · prev $34.50
1 year
−52.4%
from $71.21 · Oct 27
30 days
−19.3%
from $41.99
52-week range
$33.39–83.12
−59% from high · low Oct 19
Avg volume 20D
514
Oct 15 spike 2.1K
Short interest
682.2K
+11.7%
Price
Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.
No data for this timeframe.
- E May 15 Trial readout: T-90d Trial Readout: Petrelintide (Phase 2)
- E May 18 Trial readout: T-90d Trial Readout: Petrelintide (Phase 2)
- E May 25 Trial readout: T-90d Trial Readout: Petrelintide (Phase 2)
- X Jul 15 Short interest jumps 46.6% to 590.1K
- E Sep 9 Trial readout: Results Pending: Petrelintide (Phase 2) — Completed 27d ago
- E Oct 12 Trial readout: Results Pending: Petrelintide (Phase 2) — Completed 60d ago
Signal stack
Where each data set points today.
- Short sellersSTEADY
Short interest +11.7% to 682.2K shares.
- TrendDOWNTREND
21% below its 50-day average. New closing low $33.39 on Oct 19.
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 12, 2026 Clinical trial readout
Results Pending: Petrelintide (Phase 2) — Completed 60d ago
Trial: Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Dia
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Oct 12, 2026
Trial readout
Results Pending: Petrelintide (Phase 2) — Completed 60d ago
Trial: Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes (ZUPREME 2) Sponsor: Zealand Pharma Phase…
Sep 9, 2026
Trial readout
Results Pending: Petrelintide (Phase 2) — Completed 27d ago
Trial: Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes (ZUPREME 2) Sponsor: Zealand Pharma Phase…
Sep 8, 2026
Clinical Trial
Evaluation of Long Term Safety and Efficacy of Glepaglutide in Treatment of SBS - Extension Trial
Phase 3 · COMPLETED
Sep 8, 2026
Clinical Trial
Evaluation of Long Term Safety and Efficacy of Glepaglutide in Treatment of SBS
Phase 3 · COMPLETED
Aug 3, 2026
Clinical Trial
Extension Trial Evaluating the Long-term Safety and Efficacy of Dasiglucagon in Children With Congenital Hyperinsulinism
Phase 3 · COMPLETED
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | — | — | — | $65.0M |
| Next Q | 🔒 Fresh data, subscribers only | |||
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | 🔒 Fresh data, subscribers only | |||
Short side
FINRA· Sep 30, 2026682,212
shares short
+11.7%
vs prior settlement